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Abstract 
Purpose: To study the therapeutic effects of imperatorin (IPT) on allergic asthma induced by ovalbumin 
in rats.  
Methods: Asthma was established in rats by injection of ovalbumin (OVA), and IPT (20, 40 and 80 
mg/kg) was administered orally for 21 days. Inflammatory cells and cytokines were determined in the 
bronchoalveolar lavage fluid (BALF); IgE and histamine in the serum were also determined. 
Furthermore, MUC-5AC expression in the lung tissue was determined by Western blot assay. 
Results: Treatment with IPT (20, 40 and 80 mg/kg) decreased inflammatory cells including eosinophils 
(p < 0.01), neutrophils (p < 0.05), lymphocytes (p < 0.01) and macrophages (p < 0.01). In addition, the 
four inflammatory cytokines {interleukin (IL) -4, IL-6, IL-13 and tumor necrosis factor (TNF)-α} were 
significantly decreased by treatment with IPT (20, 40 and 80 mg/kg) dose-dependently (p < 0.01). 
Furthermore, MUC5AC in lung tissues was significantly down-regulated by treatment with IPT (20, 40 
and 80 mg/kg, p < 0.01) in a dose-dependent fashion.  
Conclusion: The results show that IPT exerts notable therapeutic effects on allergic asthma in rats via 
suppression of IgE, histamine, inflammatory cells and cytokines, and also by down-regulating MUC5AC. 
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In recent years, allergic asthma with an incidence 
rate of 4.3 % in the world has become a common 
disease affecting the normal life of millions of 
children and adults [1,2]. It is estimated that 
asthma causes over 300,000 deaths in the whole 
world every year [1-3]. Asthma is a chronic 
disease with complex pathology and 
characterized by serious airway inflammatory 
reactions, excessive phlegm and shortness of 
breath, etc. [4]. Currently, available drugs can 
temporary control or relieve the asthma 
symptoms, however radical cure of asthma 
seems very difficult. Furthermore, taking these 
drugs over a long term could cause several 
annoying adverse reactions [5,6].  
 
Herbal medicines and natural plant-derived 
agents are important sources for discovering new 
effective drugs with low toxicity [7]. Imperatorin 
(IPT, Figure 1) is a natural constituent commonly 
existing in plants of the Umbelliferae family, such 
as Peucedanum praeruptorum and Angelica 
dahurica [8]. IPT shows a broad pharmacological 
activities including anti-seizure, vasodilatation, 
antitumor, antimicrobial, anti-inflammatory, and 
analgesic effects [8-10]. However, to the best of 
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our knowledge, there is no information on the 
effects of IPT on allergic asthma. Thus, in this 
study, the therapeutic effect of IPT on allergic 
asthma was evaluated based on an ovalbumin 
(OVA) -induced asthma model in rats, and its 













Male Sprague Dawley (SD) rats (200 ± 20 g) 
were purchased from the Shanghai Laboratory 
Animal Research Center (Shanghai, China). The 
animals and experimental protocols were 
handled according to the Declaration of Helsinki 
promulgated in 1964 as amended in 1996 [10], 
and approved by the Animal Care and Use 
Committee of Zhejiang University School of 
Medicine (approval no. An-2015-0393#).  
 
Chemicals and reagents 
 
Imperatorin (IPT) was purchased from Chengdu 
Pure Chem-Standard. Co. Ltd. Chengdu, China; 
commercially enzyme-linked immunosorbent 
assay (ELISA) kits for interleukin (IL) -4, IL-13 
and tumor necrosis factor (TNF)-α were 
purchased from Invitrogen, Carlsbad, CA, USA 
and ELISA kits for IgE, IL-6, and histamine were 
obtained from eBioscience, Shanghai, China. 
OVA, pentobarbital and aluminum hydroxide 
were purchased from Sigma-Aldrich, St. Louis, 
MO. U.S.A. BCA protein assay reagent and 
horseradish peroxidase-conjugated secondary 
antibody were purchased from Beyotime, 
Nanking, China. Primary antibodies used in 
western blotting assay for MUC 5AC and β-actin 
were purchased from Abcam, Cambridge, UK.  
 
Animal model and experimental protocol 
 
A total of 50 SD rats were randomly divided into 
five groups (n=10): normal group, control group, 
and IPT groups (20, 40 and 80 mg/kg). The 
OVA-induced asthma rats were prepared 
according to the method described by Lee et al 
with minor modification [11]. Briefly, each SD rat 
in control and IPT groups were immunized by 
intraperitoneal injection (ip) of a mixture of 20 mg 
OVA and 2 mg aluminum hydroxide at 1 and 7 
days. Furthermore, rats in the control and IPT 
groups received an airway challenge with 1 % 
(w/v) OVA solution for 20 min using an ultrasonic 
nebulizer (Yuyao 402A, Nanking, China) from 
day 17 to day 21 after the initial sensitization. For 
the normal group, rats underwent the same 
sensitization procedures with saline instead of 
OVA. During this process, normal and control 
rats were orally treated with saline continuously 
from the first OVA injection to the end of the 
experiment (20 ml/kg), and rats in the IPT groups 
were administered orally with IPT at doses of 20, 
40 and 80 mg/kg, respectively.  
 
After 48 h of the final challenge, blood samples 
of the rats were collected under pentobarbital (50 
mg/kg, ip) by abdominal aortic blood sampling, 
then rats were sacrificed to obtain the 
bronchoalveolar lavage fluid (BALF) and 
inflammatory cell numbers were determined by 
counting cells with a hemocytometer. In addition, 
the lung tissues were also collected for further 
western blot assay. All the samples were stored 
at -70 °C before using.  
 
Determination of IgE and histamine in plasma 
 
Blood was centrifuged (3000 rpm) for 10 min to 
obtain plasma samples. Then, the levels of IgE 
and histamine were determined using 
commercial ELISA kits according to the 
manufacturer’s instructions. 
 
Determination of inflammatory cytokines in 
BALF 
 
The supernatants of the BALF were obtained and 
the levels of inflammatory cytokines in BALF 
including TNF-α, IL-4, IL-6 and IL-13 were 
determined using commercial ELISA kits 
according to the manufacturer’s instructions. 
 
Western blot assay 
 
Lung tissues were homogenized and then 
centrifuged at 3 000 rpm for 30 min at 4 °C, and 
subsequently total proteins were extracted from 
the supernatants. After that, protein 
concentration was determined using a BCA 
protein assay reagent. Then, equal amounts of 
total lung proteins (30 μg) were heated at 100 °C 
for 5 min and subsequently loaded onto 8 % 
sodium dodecyl sulfate polyacrylamide gel 
electrophoresis gels (SDS/PAGE), followed by 
blotting to a PVDF membrane. Nonspecific 
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binding sites of the PVDF membranes were 
blocked with 5 % skimmed milk for 1 h. After that, 
the PVDF membranes were incubated with the 
primary antibody for MUC-5AC and β-actin at 4 
°C overnight. The membranes were washed 
three times with TBST, and then incubated with 
horseradish peroxidase-conjugated secondary 
antibody for 1 h at room temperature. The target 
protein bands on the PVDF membranes were 




Data are presented as mean ± standard 
deviations (SD). Statistical comparisons were 
made by one-way analysis of variance (ANOVA) 
using SPSS software (version 15.0, USA), 
followed by Dunnett multiple comparison test. P 




Effect of IPT on inflammatory cells in BALF 
 
In order to determine the inhibitory effects of IPT 
on airway inflammatory reactions in the 
development of allergic asthma, we analysed the 
four inflammatory cells in BALF including 
eosinophils, neutrophils, lymphocytes and 
macrophages. As can be seen from Figure 2, 
BALF of OVA-challenged rats exhibited 
significant increase in these four inflammatory 
cells (p < 0.01). However, treatment with IPT at 
doses of 20, 40 and 80 mg/kg decreased the 
inflammatory cells including eosinophils (p < 
0.01), lymphocytes (p < 0.01) and macrophages 
(p < 0.01), a dose-dependent manner. In 
addition, IPT (40 and 80 mg/kg) also showed a 
significant inhibitory effects on neutrophils (p < 
0.05, p < 0.01). 
 
Effect of IPT on levels of serum IgE and 
histamine  
 
Results of the serum IgE and histamine levels in 
OVA-induced asthmatic rats are shown in Figure 
3. The levels of serum IgE and histamine in 
OVA-challenged rats were increased compared 
with normal rats (p < 0.01). Furthermore, this 
result also demonstrated that the increased 
serum IgE and histamine of OVA-challenged rats 
could be significantly decreased by treating with 
IPT (20, 40 and 80 mg/kg) dose-dependently 






Figure 2: Effect of IPT on inflammatory cells in BALF. A-D represented eosinophils, neutrophils, lymphocytes 
and macrophages, respectively. Data were expressed as mean ± SD (n = 10); *p < 0.05, **p < 0.01, compared 
with the control group 
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Figure 3: Effect of IPT on serum IgE and histamine. Data were expressed as mean ± SD (n = 10); *p < 0.05, **p 
< 0.01, compared with the control group 
 
 
Figure 4: Effect of IPT on inflammatory cytokines in BALF. Data were expressed as mean ± SD (n = 10); *p < 
0.05, **p < 0.01, compared with the control group 
 
 
Figure 5: Effect of IPT on MUC5AC protein in lung tissues. Data were expressed as mean ± SD (n = 4); *p < 
0.05, **p < 0.01, compared with the control group 
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Effect of IPT on inflammatory cytokines in 
BALF 
 
As shown in Figure 4, after injection of OVA for 3 
days, all the test inflammatory cytokines 
significantly increased including IL-4, IL-13, IL-6 
and TNF-α (p < 0.1), compared with the normal 
rats. However, it is interesting that all the four 
inflammatory cytokines were significantly 
decreased by treatment with IPT at doses of 20, 
40 and 80 mg/kg (p < 0.01) dose-dependently, 
compared with the control rats. 
 
Effect of IPT on MUC 5AC expression in lung 
tissues 
 
Furthermore, to explore the possible 
pharmacological mechanism, whether IPT down-
regulates MUC 5AC expression in lung tissues of 
OVA-challenged rats was investigated using 
western blotting assay. As can be seen from 
Figure 5, MUC5AC in rats’ lung tissues could be 
sharply up-regulated by challenging with OVA (p 
< 0.01). Furthermore, results of the present 
research demonstrated that MUC5AC could be 
significantly down-regulated by treatment with 
IPT at 20, 40 and 80 mg/kg (p < 0.01) dose-




In the present investigation, the potential 
therapeutic effects of IPT on allergic asthma 
were determined using an OVA-induced rat 
model for the first time. The results showed that 
IPT inhibited IgE, histamine, and inflammatory 
cells and cytokines in OVA-challenged rats, as 
well as down-regulated MUC5AC expression in 
lung tissue. 
 
Inflammatory reaction is an important cause in 
the development of asthma, and previous reports 
also indicated that anti-inflammatory drugs could 
be beneficial for treating or relieving asthma 
symptoms [12,13]. In this study, the results 
showed that IPT possessed significant anti-
inflammatory effects on airway inflammation 
induced by OVA via suppression of both 
inflammatory cells (eosinophils, neutrophils, 
lymphocytes and macrophages) and cytokines 
(IL-4, IL-13, IL-6 and TNF-α). Furthermore, 
previous researches indicated that asthma is 
closely related to the proliferation of allergen-
specific type II T helper (Th2) lymphocyte, 
leading to the excessive releases of Th2 
cytokines such as IL-4, and IL-13 [14,15]. Thus, 
suppression of IL-4 & IL-13 might be an 
important mechanism for the therapeutic effects 
of IPT.  
 
IgE and histamine are two important reasons for 
the development of allergic diseases including 
eczema, allergic rhinitis and asthma, etc, and 
previous researches also indicated that IgE and 
histamine are also important targets for treating 
allergic diseases [16]. Interestingly, the present 
results showed that IPT could effectively 
decrease the serum levels of IgE and histamine. 
It has been reported that hypersecretion of 
MUC5AC in airway epithelial cells is an important 
characteristic of asthma and other mucus 
hypersecretion diseases [17,18]. Down- 
regulation of MUC5AC is a feasible way for the 
treatment of hypersecretion diseases. In addition, 
it has been reported that TNF-α, IL-4 and IL-13 
play important roles in the release of MUC5AC 
[19]. The present results demonstrated that IPT 
could effectively suppress not only TNF-α, IL-4 & 




The findings of the present investigation 
demonstrate that IPT possesses effective 
therapeutic effects on allergic asthma in a rat 
model via suppression of IgE, histamine, 
inflammatory cells and cytokines, as well as by 
down-regulation of MUC5AC in OVA-induced 
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